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Abstracts A61
Rosenstock study and other two RCTs compared Glargine to Determir showed 
Glargine and Determir has not difference in HbA1c control and hypoglycemia rate 
for the patient with type 2 diabetes. Based on the Rosenstock study, cost-minimization 
study was performed. Mean daily detemir dose was higher (0.78 U/kg [0.52 with once 
daily dosing, 1.00 U/kg with twice daily dosing]) than glargine (0.44 IU/kg). Annual 
direct cost was estimated from the perspective of the health insurance in China. The 
time horizon was one year of treatment. The price was referred to Price in 2008. The 
currency is Yuan. The cost of insulin medication (glargine or determir) and consum-
able items (needles, blood glucose test strips) was collected as the direct costs. Univari-
ate sensitivity analysis on resource use and unit costs around base case parameter 
values was performed to test the robustness of the base case results RESULTS: Insulin 
glargine was associated with 40.77% (8949.05RMB per year)cost saving compared 
to insulin determir, for an equivalent level of metabolic control , although the price 
of determir is lower in China. Univariate sensitivity analysis on resource use and prices 
in Determir has been performed and conﬁrmed the robustness of the results in favour 
of insulin glargine in China. The current study ﬁndings are consistent with the direc-
tion and magnitude of cost saving reported in Spain, Hungary, Argentina, Germany 
and UK. CONCLUSIONS: Insulin glargine was cost saving compared to insulin 
determir in China. The information is importance for health care providers who are 
considering the total budget for the type 2 DM patient with basal insulin.
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COST-EFFECTIVENESS ANALYSIS OF METFORMIN COMBINED WITH 
SAXAGLIPTIN VS. METFORMIN COMBINED WITH SULFONYLUREAS IN 
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OBJECTIVES: To determine the cost-effectiveness ratio of adding saxagliptin to 
metformin therapy (SAXA+MET) compared to adding sulfonylureas (SULF+MET), in 
patients with type 2 diabetes mellitus (DM2) who have failed to achieve adequate 
glycemic control with metformin. METHODS: A discrete event simulation model 
(Cardiff Long term cost-utility model) based on UKPDS 68 with a ﬁxed time increase 
was used to simulate disease progression and to obtain an estimate of the treatment’s 
economic and health consequences in DM2 patients. The clinical efﬁcacy parameters 
for saxagliptin were obtained from the literature; drug acquisition costs, adverse 
effects (AEs) and microvascular and macrovascular complications were taken into 
account. Costs were expressed in United States dollars (2009), with an annual 3.5% 
discount. The time horizon was 20 years. RESULTS: A lower number of non-fatal 
events was found for the SAXA+MET-treated group versus the SULF+MET-treated 
group. Additionally, the model predicted a lower number of fatal events due to mac-
rovascular (146 vs. 151) and microvascular (17.7 vs. 17.9) events for the SAXA+MET-
treated group vs. the SULF+MET-treated group. The total cost of the SAXA+MET 
cohort was 14% higher than that of the SULF+MET cohort. Treatment with 
SAXA+MET resulted in a higher number of QALYs (9,392 vs. 9,172) and LYGs 
(20,898 vs. 20,797) than treatment with SULF+MET; the additional cost per QALY 
and LY gained was US$6,691 and US$ 14,656 respectively. CONCLUSIONS: Con-
sidering the GDP per capita in Argentina, results suggest that the addition of saxaglip-
tin to metformin therapy compared to the addition of sulfonylureas would yield 
acceptable cost-effectiveness ratios in DM2 patients in Argentina.
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OBJECTIVES: To assess the impact of pDPN/PHN-related health impairment on 
LOPT in patients treated with chronic pDPN/PHN. METHODS: Using data from 777 
employed adults with ≥3 months of pDPN/PHN and receiving pain medications, the 
effect of pDPN/PHN-related impairment on LOPT was estimated by: 1) single equa-
tion probit models (SEPM) assuming pain severity was exogenous, adjusting for 
respondents’ demographics, depression, anxiety, pain duration, type of pain, social 
isolation (felt alone/didn’t want to go out) and psychological distress (felt older/sleep 
difﬁculties); and 2) seemingly unrelated bivariate probit models (SUBPM), hypothesiz-
ing pain severity was endogenous and considering the same explanatory variables from 
the SEPM as instrumental variables (IVs). Pain severity was measured using a rating 
scale ranging from 0 (“no pain”) to 10 (“pain as bad as you can imagine”). RESULTS: 
Thirty percent of respondents reported LOPT. Compared to respondents without 
LOPT, respondents with LOPT were younger, male, and had more moderate/severe 
pain (all p < 0.001). Pain severity appears signiﬁcantly related with social isolation 
and psychological distress. Its relationship with LOPT appears only signiﬁcant when 
the latter variables were neglected in the SEPM or when they were used as IVs in the 
SUBPM. Marginal effects indicated that, compared to respondents with pain severity 
< 4, those with pain severity ≥4 were 19.3% more likely to incur LOPT when using 
the SEPM and, 29.5% more likely when using the SUBPM (all p < 0.001). Model 
speciﬁcation tests suggested that pain severity to be truly endogenous and that all IVs 
jointly had sufﬁcient explanatory power (all p < 0.001). CONCLUSIONS: Pain sever-
ity has a signiﬁcant impact on LOPT. The degree of this impact depends on ones’ 
ideas about how this impact is mediated by respondents’ social isolation and psycho-
logical distress. Alternative IVs for adjusting endogeneity bias of pain severity are 
worth exploring.
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OBJECTIVES: The purpose of this study is to consider the extent to which estimates 
of the impact of diabetes on employment status, absenteeism and presenteeism varies 
between China and Japan. METHODS: Data from the 2008 and 2009 National 
Health and Wellness Surveys undertaken in Japan and urban China were used to 
estimate a logistic employment status model and ordered probit regression analyses 
of the determinants of absenteeism and presenteeism for those employed full-time, 
part-time or self employed. Absenteeism was determined by respondents indicating 
time off due to ill health in the past seven days; presenteeism was determined by 
respondents assessing the extent to which workplace productivity was impacted by 
their health status in the same time period. Apart from diabetic status the models 
included demographic and socio-economic characteristics, the Charlson Comorbidity 
Index, together with health risk factors and controls for absenteeism experience and 
diagnosed diabetes. RESULTS: In both China and Japan a diagnosis of diabetes was 
found to have a signiﬁcant (1% level) negative impact on employment status (odds 
ratios 0.540 and 0.796 respectively). The results for absenteeism point once again to 
the signiﬁcant (at 1% level) positive impact of diabetes on higher rates of absenteeism 
with odds ratios of 3.057 for China but only 1.410 respectively for Japan. In the case 
of presenteeism the impact of diabetes is still signiﬁcant (1% level) in the case of China, 
but less so for Japan (odds ratios 2.102 and 1.179 respectively). CONCLUSIONS: 
The presence of diabetes has a signiﬁcant and negative impact on workforce status as 
well as on absenteeism in China and Japan. Both countries show similar impacts, 
although in Japan the impact on presenteeism is less marked.
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OBJECTIVES: The purpose of this study is to consider the extent to which estimates 
of the impact of diabetes on presenteeism can vary between major industrial countries 
and to assess the relative contribution of absenteeism, socio-demographic and health 
risk factors. METHODS: Data from the 2008 National Health and Wellness Survey, 
a national survey of ﬁve EU countries (the UK, France Spain, Germany and Italy) were 
used to estimate an ordered probit regression analysis of the determinants of presentee-
ism for those employed full-time, part-time or self employed. Presenteeism was deter-
mined by respondents assessing the extent to which workplace productivity was 
impacted by their health status on a 10-point scale. The model includes health risk 
factors (BMI, alcohol use, smoking), the Charlson Comorbidity Index (CCI) along 
with controls for absenteeism experience and diagnosed diabetes. RESULTS: Absen-
teeism, the percentage of time lost in the previous seven days, was the dominant factor 
impacting presenteeism for all countries (odds ratios 16.17 Germany to 9.23 Italy). 
With the exception of Spain, obesity and morbid obesity had a positive and signiﬁcant 
impact with odds ratios in the range 1.33 – 1.04 and 2.08 – 1.60 respectively. The 
presence of diabetes was signiﬁcant for all countries with odds ratios ranging from 
1.29 (Italy) to 1.77 ( Spain). Replacing diabetes with the CCI resulted in signiﬁcant 
odds ratios in the range 1.33 (Germany) to 1.17 ( UK). CONCLUSIONS: The presence 
of diabetes has a signiﬁcant and negative impact on workplace presenteeism. The 
impact of diabetes is of a similar order of magnitude to the presence of obesity and 
morbid obesity.
DIABETES/ENDOCRINE DISORDERS – Patient-Reported Outcomes Studies
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BELIEFS AND EXPECTATIONS ABOUT DIABETES AND MEDICATION 
ADHERENCE IN PERSONS WITH TYPE 2 DIABETES
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OBJECTIVES: Associations between type 2 diabetic patients’ beliefs and expectations 
about their illness and medication adherence were determined. METHODS: A cross-
sectional self-administered written survey of type 2 diabetes patients was conducted 
in an outpatient pharmacy, at a primary care clinic afﬁliated with a hospital serving 
an urban population. Study inclusion criteria were being 18 years or older, diagnosed 
with type 2 diabetes at least 6 months prior to the time of the survey, and taking oral 
anti-diabetic medication. Exclusion criteria were use of insulin or not being able to 
read and write in English. The survey included the Brief Illness Perception Question-
naire (B-IPQ) to assess individuals’ illness beliefs and the Morisky 8-item Medication 
Adherence Scale to collect self-reported adherence. Chi-square tests of association and 
Pearson correlation analysis were used to assess whether illness beliefs were associated 
with adherence. RESULTS: Two-hundred and ﬁve completed responses were obtained 
from 354 individuals who satisﬁed inclusion and exclusion criteria, for a response rate 
of 58%. The sample was 50% Caucasian, 50% African-American, 63% female and 
72% had annual household income of less than $25,000. A majority (56%) reported 
